Affirmed Therapeutics BV (AFMD) Short Interest Update
Affirmed Therapeutics BV (NASDAQ:AFMD) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 996,488 shares, a growth of 31.2% from the August 31st total of 759,494 shares. Approximately 5.4% of the company’s shares are sold short. Based on an average trading volume of 80,338 shares, the short-interest ratio is currently 12.4 days.
Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in Affirmed Therapeutics BV by 6.8% in the first quarter. Geode Capital Management LLC now owns 29,204 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,856 shares in the last quarter. Paloma Partners Management Co bought a new stake in shares of Affirmed Therapeutics BV during the second quarter worth about $142,000. Moore Capital Management LP bought a new stake in shares of Affirmed Therapeutics BV during the first quarter worth about $281,000. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Affirmed Therapeutics BV by 1.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 108,911 shares of the biopharmaceutical company’s stock worth $407,000 after buying an additional 1,713 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Affirmed Therapeutics BV by 7.7% in the first quarter. State Street Corp now owns 220,885 shares of the biopharmaceutical company’s stock worth $823,000 after buying an additional 15,714 shares during the last quarter. Hedge funds and other institutional investors own 42.86% of the company’s stock.
Affirmed Therapeutics BV (NASDAQ:AFMD) opened at 2.54 on Friday. Affirmed Therapeutics BV has a 12 month low of $2.34 and a 12 month high of $8.42. The firm’s 50-day moving average is $2.75 and its 200-day moving average is $3.24. The firm’s market capitalization is $85.06 million.
Affirmed Therapeutics BV (NASDAQ:AFMD) last released its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by $0.05. Affirmed Therapeutics BV had a negative return on equity of 49.84% and a negative net margin of 440.97%. The firm earned $2.07 million during the quarter, compared to analyst estimates of $2.10 million. During the same quarter in the prior year, the company posted ($0.19) EPS. The company’s quarterly revenue was down 6.4% on a year-over-year basis. On average, equities research analysts expect that Affirmed Therapeutics BV will post ($1.12) EPS for the current year.
AFMD has been the topic of several research analyst reports. Leerink Swann raised shares of Affirmed Therapeutics BV from a “market perform” rating to an “outperform” rating in a research report on Monday, July 18th. Jefferies Group reissued a “hold” rating on shares of Affirmed Therapeutics BV in a research report on Tuesday, August 9th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $8.63.
Affirmed Therapeutics BV Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Ratings for Affirmed Therapeutics BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affirmed Therapeutics BV and related companies with MarketBeat.com's FREE daily email newsletter.